GliaPharm is a Swiss biotechnology company that develops treatments for neurological and psychiatric disorders.
GliaPharm est une entreprise suisse de biotechnologies active dans le développement de traitements de maladies neurologiques et psychiatriques.
GliaPharm receives grant for collaboration with HEPIA to setup a new 3D culture method using brain organoids from mouse and human-derived cells
GliaPharm presented at the European Congress of Neuropsychopharmacology - Symposium on "Beyond the Neurocentric Paradigm: Targeting Astrocytes and Neuroglial Interactions in CNS Disorders". September 13th 2020.
GliaPharm participated at the virtual #FOXG1ScienceSymposium on August 17/18. Register here to tune in to hear from all the researchers, industry and more about the path to a cure for #FOXG1. #FOXG1SS2020